JP2008505636A5 - - Google Patents

Download PDF

Info

Publication number
JP2008505636A5
JP2008505636A5 JP2007520225A JP2007520225A JP2008505636A5 JP 2008505636 A5 JP2008505636 A5 JP 2008505636A5 JP 2007520225 A JP2007520225 A JP 2007520225A JP 2007520225 A JP2007520225 A JP 2007520225A JP 2008505636 A5 JP2008505636 A5 JP 2008505636A5
Authority
JP
Japan
Prior art keywords
seq
nos
sequences
cloning
primer sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007520225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008505636A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2005/002111 external-priority patent/WO2006004362A1/en
Publication of JP2008505636A publication Critical patent/JP2008505636A/ja
Publication of JP2008505636A5 publication Critical patent/JP2008505636A5/ja
Pending legal-status Critical Current

Links

JP2007520225A 2004-07-03 2005-07-04 Ｈｃｖに有効なｃｔｌ反応を誘導するスーパータイプのエピトープ、これをコードするオリゴヌクレオチド並びにそれらの用途 Pending JP2008505636A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20040051782 2004-07-03
PCT/KR2005/002111 WO2006004362A1 (en) 2004-07-03 2005-07-04 Supertype epitopes, oligonucleotides coding the same which induce effective ctl response against hcv and the use thereof

Publications (2)

Publication Number Publication Date
JP2008505636A JP2008505636A (ja) 2008-02-28
JP2008505636A5 true JP2008505636A5 (enExample) 2008-07-31

Family

ID=35783125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007520225A Pending JP2008505636A (ja) 2004-07-03 2005-07-04 Ｈｃｖに有効なｃｔｌ反応を誘導するスーパータイプのエピトープ、これをコードするオリゴヌクレオチド並びにそれらの用途

Country Status (6)

Country Link
US (1) US20080112977A1 (enExample)
EP (1) EP1778719A1 (enExample)
JP (1) JP2008505636A (enExample)
KR (1) KR100790646B1 (enExample)
CN (1) CN1976946A (enExample)
WO (1) WO2006004362A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114617954A (zh) * 2007-09-18 2022-06-14 亮径生物疗法有限公司 Ctl诱导剂组合物
CN102174522B (zh) * 2011-02-24 2013-11-06 杭州师范大学 一种4-1bbl蛋白的制备方法
WO2016079143A1 (de) 2014-11-17 2016-05-26 Pharis Biotec Gmbh Inhibitor der viralen hepatitis c infektion
CN107827959B (zh) * 2017-11-09 2018-10-30 杭州续缓生物科技有限公司 识别乙肝病毒(hbv)表面抗原s183-91表位的tcr及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607727B1 (en) * 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
EP0703783B1 (en) * 1993-03-05 2010-05-05 Epimmune Inc. Methods of making immunogenic hla-a2.1 binding peptides
ES2197170T3 (es) * 1993-11-04 2004-01-01 Innogenetics N.V. Epitopos de celulas t humanas inmunologicamente dominantes del virus de la hepatitis c.
US6235888B1 (en) * 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
DE69935599T2 (de) * 1998-08-21 2007-11-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Modifizierte hcv peptid-impfstoffe
CA2678259C (en) * 1998-12-09 2016-10-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
WO2001030812A2 (en) * 1999-10-27 2001-05-03 Chiron Corporation Activation of hcv-specific t cells
AU2001256970C1 (en) * 2000-03-31 2008-07-03 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US20020172682A1 (en) * 2000-10-20 2002-11-21 University Of Connecticut Health Center Using heat shock proteins to increase immune response
JP2003064096A (ja) 2001-08-29 2003-03-05 Mitsubishi Kagaku Bio-Clinical Laboratories Inc Ｃ型肝炎ウイルス特異的細胞障害性ｔ細胞認識エピトープ

Similar Documents

Publication Publication Date Title
JP2010534684A5 (enExample)
JP2006527780A5 (enExample)
CL2008003684A1 (es) Composicion farmaceutica que comprende una sal de aluminio, que tiene una relacion molar de aluminio a cloruro de 0,3:1 a 3:1 aproximadamente, ademas comprende zirconio; metodo de preparacion de la composicion; uso como antitranspirante.
JP2006526031A5 (enExample)
JP2011527560A5 (enExample)
AR075882A1 (es) Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
JP2010501534A5 (enExample)
WO2009022236A8 (en) Immunogen platform
JP2013509879A5 (enExample)
JP2011508438A5 (enExample)
AR071891A1 (es) Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
JP2011518833A5 (enExample)
JP2009542225A5 (enExample)
NO20083406L (no) FGF-reseptorer for dimere forbindelser
ATE496629T1 (de) Impfstoff gegen felines calicivirus (fcv), der ein fcv kapsid protein oder ein isoliertes fcv kapsid protein mit der protein sequenz seq id no: 13 oder mit einer protein sequenz, die zumindestens zu 95 identisch zur seq id no: 13 ist enthält.
JP2007510403A5 (enExample)
JP2005515295A5 (enExample)
ZA200907242B (en) Nucleic acids
AR049681A1 (es) Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas
JP2009501689A5 (enExample)
JP2008505636A5 (enExample)
JP2007523200A5 (enExample)
WO2005063787A3 (en) Propargyl substituted nucleoside compounds and methods
JP2007277223A5 (enExample)